{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:16:38Z","timestamp":1758816998186},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1097\/01.ju.0000086360.86537.cb","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T22:33:54Z","timestamp":1093473234000},"page":"2467-2470","source":"Crossref","is-referenced-by-count":5,"title":["Optimal Administration Schedule of Cisplatin for Bladder Tumor With Minimal Induction of Metallothionein"],"prefix":"10.1097","volume":"170","author":[{"given":"YUKIHIRO","family":"KONDO","sequence":"first","affiliation":[{"name":"From the Department of Urology, Nippon Medical School, Bunkyo-ku and Department of Public Health and Molecular Toxicology, School of Pharmaceutical Science, Kitasato University, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENJI","family":"YAMAGATA","sequence":"additional","affiliation":[{"name":"From the Department of Urology, Nippon Medical School, Bunkyo-ku and Department of Public Health and Molecular Toxicology, School of Pharmaceutical Science, Kitasato University, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAHIKO","family":"SATOH","sequence":"additional","affiliation":[{"name":"From the Department of Urology, Nippon Medical School, Bunkyo-ku and Department of Public Health and Molecular Toxicology, School of Pharmaceutical Science, Kitasato University, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SEIICHIRO","family":"HIMENO","sequence":"additional","affiliation":[{"name":"From the Department of Urology, Nippon Medical School, Bunkyo-ku and Department of Public Health and Molecular Toxicology, School of Pharmaceutical Science, Kitasato University, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NOBUMASA","family":"IMURA","sequence":"additional","affiliation":[{"name":"From the Department of Urology, Nippon Medical School, Bunkyo-ku and Department of Public Health and Molecular Toxicology, School of Pharmaceutical Science, Kitasato University, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAIJI","family":"NISHIMURA","sequence":"additional","affiliation":[{"name":"From the Department of Urology, Nippon Medical School, Bunkyo-ku and Department of Public Health and Molecular Toxicology, School of Pharmaceutical Science, Kitasato University, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1097\/01.ju.0000086360.86537.cb_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","article-title":"Cancer Statistics, 2000","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)48996-8","article-title":"Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium","volume":"133","author":"Sternberg","year":"1985","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","article-title":"Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study","volume":"3","author":"Harker","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib5","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","article-title":"Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"15","author":"Saxman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0027-5107(01)00141-5","article-title":"Mechanisms of resistance to cisplatin","volume":"478","author":"Kartalou","year":"2001","journal-title":"Mutat Res"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib7","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1124\/mol.60.6.1153","article-title":"Identification of genes that mediate sensitivity to cisplatin","volume":"60","author":"Niedner","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1146\/annurev.biochem.55.1.913","article-title":"Metallothionein","volume":"55","author":"Hamer","year":"1986","journal-title":"Annu Rev Biochem"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00018-002-8454-2","article-title":"Metallothionein: the multipurpose protein","volume":"59","author":"Coyle","year":"2002","journal-title":"Cell Mol Life Sci"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib10","first-page":"2021","article-title":"Metallothionein null cells have increased sensitivity to anticancer drugs","volume":"55","author":"Kondo","year":"1995","journal-title":"Cancer Res"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib11","first-page":"474","article-title":"Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines","volume":"55","author":"Kondo","year":"1995","journal-title":"Cancer Res"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1006\/bbrc.1998.8509","article-title":"Metallothionein-mediated resistance to multiple drugs can be induced by several anticancer drugs in mice","volume":"245","author":"Okazaki","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib13","first-page":"1829","article-title":"Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis","volume":"53","author":"Satoh","year":"1993","journal-title":"Cancer Res"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s002400050103","article-title":"Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins","volume":"27","author":"Siegsmund","year":"1999","journal-title":"Urol Res"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib15","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.238.21.2282","article-title":"Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report","volume":"238","author":"Sternberg","year":"1977","journal-title":"JAMA"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00686330","article-title":"Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor","volume":"29","author":"Kondo","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib17","first-page":"50","article-title":"Chemotherapy of human tumor xenografts in genetically athymic mice","volume":"8","author":"Ovejera","year":"1978","journal-title":"Ann Clin Lab Sci"},{"key":"10.1097\/01.ju.0000086360.86537.cb_bib18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J Clin Invest"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534705628881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534705628881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1097\/01.ju.0000086360.86537.cb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:22:50Z","timestamp":1651213370000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1097\/01.ju.0000086360.86537.cb"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1097\/01.ju.0000086360.86537.cb"],"URL":"https:\/\/doi.org\/10.1097\/01.ju.0000086360.86537.cb","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}